Supplementary Material from <i>In silico</i> simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model

Supplemental figures and tables can be found in Supplementary Material: anti-CTLA-4 monotherapy and combination therapy using high doses of tremelimumab; anti-CTLA-4 monotherapy and combination therapy using continuous doses of tremelimumab; waterfall plot; personalized prediction with only changing tumor growth rate; personalized prediction with only changing antigen intensity; personalized prediction with only changing PD-L1 expression; optimization results; model species, parameters, reaction rates, and algebraic equations. (ZIP 2.4 MB